Maryland-based Emergent BioSolutions, which is recovering from regulatory woes in the wake of COVID-19 vaccine production problems, has elevated Deputy General Counsel Jennifer Fox to general counsel.

Fox, who joined Emergent in 2018 as an associate general counsel, will now serve as executive vice president, external affairs, general counsel, and corporate secretary. She replaces Atul Saran, executive vice president and general counsel. Saran now will serve as chief strategy and development officer.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]